Tao Chen, Rong-Hong Zhang, Shi-Chao He, Qin-Yuan Xu, Liang Ma, Guang-Cheng Wang, Neng Qiu, Fei Peng, Jin-Ying Chen, Jing-Xiang Qiu, Ai-Hua Peng, Li-Juan Chen
Index: Molecules 17(6) , 6249-68, (2012)
Full Text: HTML
Gambogic acid (GA) is in a phase II clinical trial as an antitumor and antiangiogenesis agent. In this study, 36 GA derivatives were synthesized and screened in a zebrafish model to evaluate their antiangiogenic activity and toxicity. Derivatives 4, 32, 35, 36 effectively suppressed the formation of newly grown blood vessels and showed lower toxicities than GA as evaluated by zebrafish heart rates and mortalities. They also exhibited more potent migration and HUVEC tube formation inhibiting activities than GA. Among them, 36 was the most potent one, suggesting that it may serve as a potential new antiangiogenesis candidate with low toxicity. Additionally, 36 showed comparable antiproliferative activity to HUVECs and five tumor cell lines but low cytotoxicity to LO2 cells.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Gambogic Acid
CAS:2752-65-0 |
C38H44O8 |
Induction of programmed erythrocyte death by gambogic acid.
2012-01-01 [Cell Physiol. Biochem. 30(2) , 428-38, (2012)] |
Gambogic acid as a non-competitive inhibitor of ATP-binding ...
2013-01-01 [Basic Clin Pharmacol Toxicol. 112(1) , 25-33, (2013)] |
Subcellular localization and activity of gambogic acid.
2012-05-29 [ChemBioChem. 13(8) , 1191-8, (2012)] |
Studies on chemical structure modification and structure-act...
2012-08-01 [Chem. Biodivers. 9(8) , 1579-90, (2012)] |
Interaction between Gambogic acid and dihydrofolate reductas...
2013-01-01 [Anticancer Res. 33(1) , 133-42, (2013)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved